MDACC Study No:2012-1106(2011-0554SOLIDTUM) ( NCT No: NCT01461538)
Title:A phase 2, open-label study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies
Principal Investigator:Jorge Cortes
Treatment Agent:Brentuximab Vedotin
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if Adcetris™ (brentuximab
vedotin) can help to control advanced or metastatic leukemia that has the CD30
marker. The safety of this drug will also be studied.

Brentuximab vedotin is designed to stop tumor growth in cancer that has the
CD30 tumor marker.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Brentuximab Vedotin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults